Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus
Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus
复制标题
DOI：
10.1056/nejm199803263381303
复制
发表时间：
1998-03-26
影响因子：
158.5
通讯作者：
Shulman, GI
中科院分区：
文献类型：
--
作者：
Inzucchi, SE;Maggs, DG;Shulman, GI
背景 联合治疗对于非胰岛素依赖型（II 型）糖尿病患者来说是合乎逻辑的，因为他们通常对单一药物治疗反应不佳。我们研究了二甲双胍和曲格列酮单药和联合用药对 II 型糖尿病患者的疗效和生理效应。方法我们随机分配 29 名患者接受二甲双胍或曲格列酮治疗 3 个月，之后再接受这两种药物治疗 3 个月。在两种治疗期间定期测量空腹和餐后血浆葡萄糖浓度以及糖化血红蛋白值。在基线以及三个月和六个月后测量内源性葡萄糖产生和外周葡萄糖处理。 结果 在二甲双胍治疗期间，空腹和餐后血浆葡萄糖浓度降低了 20%（58 毫克每分升 [3.2 毫摩尔每升]，P
Background Combination therapy is logical for patients with non-insulin-dependent (type II) diabetes mellitus, because they often have poor responses to single-drug therapy. We studied the efficacy and physiologic effects of metformin and troglitazone alone and in combination in patients with type II diabetes.Methods We randomly assigned 29 patients to receive either metformin or troglitazone for three months, after which they were given both drugs for another three months. Plasma glucose concentrations during fasting and postprandially and glycosylated hemoglobin values were measured periodically during both treatments. Endogenous glucose production and peripheral glucose disposal were measured at base line and after three and six months.Results During metformin therapy, fasting and postprandial plasma glucose concentrations decreased by 20 percent (58 mg per deciliter [3.2 mmol per liter], P